PYXS PYXIS ONCOLOGY INC

Pyxis Oncology to Participate in September Investor and Industry Conferences

Pyxis Oncology to Participate in September Investor and Industry Conferences

BOSTON, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing antibody-drug conjugate (ADC) therapeutics for difficult-to-treat cancers, today announced that Lara S. Sullivan, M.D., President, Chief Executive Officer and Chief Medical Officer, will participate in the following upcoming conferences.

Investor Conferences

  • 2025 Cantor Global Healthcare Conference, New York, NY, Wednesday, September 3, 2:45 p.m. ET – Fireside chat and investor one-on-one meetings.



  • H.C. Wainwright 27th Annual Global Investment Conference, New York, NY, Monday, September 8, 10:30 a.m. ET – Fireside chat and investor one-on-one meetings.

Industry Conference

  • 2nd Annual ADC and Novel Conjugates Partnering and Investment Summit, Boston, MA, Tuesday, September 9, 3:20 p.m. ET – Company presentation (not webcast).

Live webcasts and replays of the Cantor and H.C. Wainwright fireside chats will be available on the Events & Presentations page in the Investor Relations section of Pyxis Oncology’s website, .

About Pyxis Oncology, Inc.

Pyxis Oncology, Inc. is a clinical stage company focused on defeating difficult-to-treat cancers. The Company is efficiently building therapeutics that hold the potential for monotherapy and combination indications. Its lead candidate, micvotabart pelidotin (MICVO, formerly PYX-201), has been evaluated in ongoing Phase 1 clinical studies in multiple types of solid tumors with a go-forward development focus on treating patients with recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC) based on the strength of the HNSCC signal that emerged. Additionally, the Company initiated a Phase 1/2 combination study of MICVO and Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), in patients with R/M HNSCC and other advanced solid tumors.

To learn more, visit  or follow us on  and .

Pyxis Oncology Contact

Jitu Wadhane

Principal Financial and Accounting Officer

Media

Molly Devlin

Real Chemistry



EN
21/08/2025

Underlying

PYXSPYXIS ONCOLOGY INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on PYXIS ONCOLOGY INC

 PRESS RELEASE
Free
PYXS PYXIS ONCOLOGY ...

Pyxis Oncology to Participate in September Investor and Industry Confe...

Pyxis Oncology to Participate in September Investor and Industry Conferences BOSTON, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing antibody-drug conjugate (ADC) therapeutics for difficult-to-treat cancers, today announced that Lara S. Sullivan, M.D., President, Chief Executive Officer and Chief Medical Officer, will participate in the following upcoming conferences. Investor Conferences 2025 Cantor Global Healthcare Conference, New York, NY, Wednesday, September 3, 2:45 p.m. ET – Fireside chat and investor one-on-one meetings....

7h 1 EN
 PRESS RELEASE
Free
PYXS PYXIS ONCOLOGY ...

Pyxis Oncology Reports Second Quarter 2025 Financial Results and Provi...

Pyxis Oncology Reports Second Quarter 2025 Financial Results and Provides Business Update –  Phase 1 monotherapy expansion study of micvotabart pelidotin (MICVO) for recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC) patients progressing well with preliminary data in second half of 2025 and first half of 2026 –  Phase 1/2 combination study of MICVO and KEYTRUDA® (pembrolizumab) progressing well with preliminary data in second half of 2025 –  Received a $2.8 million, net of tax, milestone payment from Simcere Pharmaceutical Group Limited for approval of suvemcitug (...

August 14, 2025 1 EN
 PRESS RELEASE
Free
PYXS PYXIS ONCOLOGY ...

Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 563...

Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BOSTON, June 30, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation antibody-drug conjugate (‘ADC’) therapeutics for difficult-to-treat cancers, reported today that Pyxis Oncology’s Compensation Committee of the Board of Directors granted stock options to purchase an aggregate of 246,238 shares of Pyxis Oncology’s common stock to four newly hired employees. The awards were granted under the Pyxis Oncology, Inc. 2022 Inducement Plan (the ‘Plan’) with ...

June 30, 2025 1 EN
 PRESS RELEASE
Free
PYXS PYXIS ONCOLOGY ...

Pyxis Oncology Reports First Quarter 2025 Financial Results and Provid...

Pyxis Oncology Reports First Quarter 2025 Financial Results and Provides Business Update - Announced robust preclinical data supporting the unique three-pronged mechanism of action of micvotabart pelidotin (MICVO, formerly PYX-201), driving anti-tumor activity via direct tumor killing, bystander effect and immunogenic cell death - On track to report preliminary data from Phase 1 monotherapy expansion cohorts of MICVO for 2L/3L R/M HNSCC patients who have received prior platinum-based chemotherapy and prior PD-(L)1 inhibitor therapy in second half of 2025, and 2L/3L R/M HNSCC patients who...

May 15, 2025 1 EN
 PRESS RELEASE
Free
PYXS PYXIS ONCOLOGY ...

Pyxis Oncology to Participate in Two Upcoming Investor Conferences

Pyxis Oncology to Participate in Two Upcoming Investor Conferences BOSTON, May 14, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation ADC therapeutics for difficult-to-treat cancers, today announced that Lara S. Sullivan, M.D., President, Chief Executive Officer and Chief Medical Officer, will participate in fireside chats and be available for one-on-one meetings with investors at the following two upcoming investor conferences. 2025 RBC Capital Markets Global Healthcare Conference in New York, NY on Wednesday, May 21 at 2:05...

May 14, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch